Glazer Capital Discloses New 8.15% Passive Stake in Esperion Therapeutics

On June 8, 2026, Glazer Capital, LLC and its Managing Member, Paul J. Glazer, filed a Schedule 13G with the SEC, disclosing a significant new ownership stake in Esperion Therapeutics, Inc. (ESPR). The reporting persons disclosed beneficial ownership of 20,975,620 shares of common stock, representing 8.15% of the company's outstanding shares. The event triggering this filing occurred on June 1, 2026. Glazer Capital serves as the investment manager for various funds and managed accounts, including the Glazer Capital Enhanced Master Fund, Ltd., which specifically holds the right to receive dividends or sale proceeds for more than 5% of the issuer's common stock. The filing was made under Rule 13d-1(c), indicating a passive investment intent. The reporting persons share voting and dispositive power over all reported shares. This position marks a substantial increase from zero reported holdings in the previous period, establishing Glazer Capital as a major institutional shareholder in the Ann Arbor-based pharmaceutical company.